Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linvoseltamab Plus Other Treatments in Relapsed/Refractory Multiple Myeloma
NCT05137054Phase 1Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2022
- Primary completion
- Mar 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 1, open-label trial of linvoseltamab in multiple myeloma (MM) (10 cohorts), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Incidence of Dose Limiting Toxicities at 28 days, Incidence of Treatment-Emergent Adverse Events at 5 years and 6 more. Started Aug 2022; status: recruiting.
02
Drugs
linvoseltamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05137054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05137054.